NCT03461952: Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: POLE, POLD
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must have solid tumors that demonstrate POLE or POLD1 mutations
Exclusions: Active & unstable brain metastases or leptomeningeal metastases; Primary CNS tumors- see trial for details

Comments are closed.

Up ↑